ImpediMed Limited
Suite 31C, 12-18 Tryon Rd
Lindfield NSW 2070
Australia
E: investorrelations@impedimed.com
W : impedimed.com

18 November 2026

Companies Announcements Office
Australian Securities Exchange

2026 Annual General Meeting – Chair's Address

ImpediMed Limited (**ImpediMed**) (ASX:IPD) provides the attached Chair's Address to be delivered at today's Annual General Meeting commencing at 11.00am AEDT.

Approved for release by the Board of ImpediMed Limited.

For more information, contact Leanne Ralph, Company Secretary, at leanne.ralph@bellev.com.au

Annual General Meeting
18 November 2026

Chair's Address - Ms Christine Emmanuel-Donnelly

Ladies and Gentlemen,

Good morning and welcome to the 2026 Annual General Meeting of ImpediMed Limited.

On behalf of the Board, I would like to thank our shareholders for your continued support. I would also like to acknowledge our employees, healthcare partners and the patients whose lives are improved through the use of our technology.

The past year has been one of significant transition and important progress for the Company. While market conditions remain challenging and our share price performance has been disappointing, we have continued to strengthen the foundations of the business, focus on commercial execution and position ImpediMed for the next phase of growth.

During the year, revenue increased by 15%, or 20% in constant currency, and US reimbursement coverage expanded to 95%. We also implemented initiatives to deliver approximately $5 million in annualised cost savings, with benefits already emerging in our financial results. These outcomes reflect the disciplined work undertaken over recent years to strengthen the Company's operational and financial position.

The Board also reviewed its skills and composition, resulting in the appointment of Erik Anderson as a Non-Executive Director in early 2026. Erik brought more than 20 years of commercial leadership experience in the US medical device sector, including his most recent role as Division President of the Breast and Skeletal Health business at Hologic. His experience and commercial expertise strengthened the Board and, following the departure of Dr Parmjot Bains, he was appointed Chief Executive Officer.

I would like to acknowledge and thank Parmjot for her leadership and contribution over the past two years. Under her leadership, the Company established important foundations for the expansion of the SOZO platform into body composition for weight management and fluid status monitoring in heart health. These opportunities remain important components of our long-term growth strategy.

In May, the Company completed a capital raising of $15.2 million through a placement and Share Purchase Plan. This was achieved during a particularly challenging period for healthcare and small-cap businesses and demonstrated the continued support of both existing and new shareholders. We thank all investors who participated and continue to support the Company's strategy.

The Board recognises that we are all disappointed with the current share price which significantly undervalues the business. While a range of factors have influenced recent trading performance, the Board remains focused on the drivers of shareholder value: commercial execution, revenue growth, disciplined capital management and continued market adoption of SOZO.

Since late 2023, the refreshed Board's focus has been to reposition ImpediMed for sustainable commercial success. Significant progress had been made previously in securing reimbursement coverage, strengthening clinical evidence, supporting guideline inclusion and expanding market access. These achievements were essential prerequisites to commercial growth. Although we continue to support the business in these areas, our focus is on execution, adoption and the creation of sustainable shareholder value.

Turning briefly to the Remuneration Report, I note that it relates to remuneration outcomes for the previous financial year and does not include the proposed incentive arrangements for our CEO, which are the subject of a separate resolution. During the year, the Board reduced cash remuneration and maintained alignment with shareholders through equity participation. In addition, no Transformation Incentive payment was made to staff because the applicable performance hurdles were not achieved.

With respect to Resolution 6, the Board believes the proposed long-term incentive award for Erik Anderson appropriately aligns executive reward with shareholder outcomes. The structure rewards share price appreciation and requires the achievement of challenging performance hurdles before value can be realised. We will address any questions on this resolution during the formal discussion.

Looking ahead, our priorities are clear. We will continue to focus on disciplined commercial execution, prudent financial management and expanding the clinical and commercial opportunity for SOZO Health, moving beyond the shackles of our previous brand history. We are encouraged by the momentum being generated within the business, the calibre of talent being attracted to the organisation and the growing recognition of SOZO as a standard of care in both lymphoedema and cancer survivorship assessment and management. I look forward to Erik providing furher detail on these developments.

While challenges remain, we believe the Company is increasingly well positioned to capture the significant opportunities ahead. The Board remains committed to making transformative decisions as necessary that creates value for shareholders, provides certainty for our employees and improves outcomes for patients.

On behalf of the Board, thank you for your continued support and engagement.

I will now invite Erik Anderson to provide a more detailed update on the Company's operations, and commercial progress.

Thank you